Persson E
Department of Anaesthesia, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden.
Acta Med Scand Suppl. 1988;724:1-56.
Heparin activates lipoprotein lipase (LPL) and hepatic lipase (HL), enhances plasma lipolytic activity and elevates plasma levels of free fatty acids (FFA). The metabolic consequences of this effect are controversial. In this study the plasma lipolytic effect of unfractionated heparin (mean molecular weight, MW, 12,000-15,000) was compared with that of a low molecular weight heparin (LMWH) fragment (Kabi 2165, Fragmin, mean MW 4000-6000). The comparisons which were carried out in vivo and in vitro in both man and rat were based on the antifactor Xa activity of the two heparins. After i.v. injection of LMWH the release of LPL activity was only half as great as with heparin and the increase in plasma FFA was significantly lower. The immediate release of HL activity was the same for both heparins, the release of LPL activity was dose-dependent and the elimination followed first-order kinetics. After subcutaneous administration, LMWH was absorbed faster than heparin but still had a negligible effect on plasma lipolysis. With simultaneous i.v. infusions of fat emulsion, glucose and heparin or LMWH to healthy subjects no different effects on fat oxidation were seen in spite of pathological increases in plasma FFA with heparin. Also, heat production from isolated adipocytes was not affected by heparin or LMWH. Enzyme release was greater with LMWH in tissue preparations of fat, skeletal muscle and heart muscle in vitro, however. In isolated fat cells no difference in the release of LPL was seen between the two heparins. In conclusion, the plasma lipolytic effect of LMWH is significantly weaker than that of heparin. The complex-binding between heparin and LPL is dependent on the degree of sulphation or ionic strength of the heparin. In the LPL-release from tissue preparations, the molecular size of the heparin is of greater significance, however. Regardless of the degree of plasma lipolytic activity of the two heparin preparations, the fat oxidation rate is not affected. Considering the toxic effects of high levels of plasma FFA, LMWH, with its weak lipolytic potential would appear to be preferable to heparin as an anticoagulant agent.
肝素可激活脂蛋白脂肪酶(LPL)和肝脂肪酶(HL),增强血浆脂解活性,并提高血浆游离脂肪酸(FFA)水平。这种作用的代谢后果存在争议。在本研究中,将普通肝素(平均分子量,MW,12,000 - 15,000)的血浆脂解作用与低分子量肝素(LMWH)片段(卡比2165,法安明,平均MW 4000 - 6000)的血浆脂解作用进行了比较。在人和大鼠体内及体外进行的比较是基于两种肝素的抗Xa因子活性。静脉注射LMWH后,LPL活性的释放仅为肝素的一半,血浆FFA的升高也显著更低。两种肝素HL活性的即时释放相同,LPL活性的释放呈剂量依赖性,消除遵循一级动力学。皮下给药后,LMWH的吸收比肝素快,但对血浆脂解的影响仍然可以忽略不计。对健康受试者同时静脉输注脂肪乳剂、葡萄糖和肝素或LMWH,尽管肝素使血浆FFA出现病理性升高,但对脂肪氧化未见不同影响。此外,肝素或LMWH对分离的脂肪细胞的产热也无影响。然而,在体外脂肪、骨骼肌和心肌组织制剂中,LMWH的酶释放量更大。在分离的脂肪细胞中,两种肝素之间LPL的释放未见差异。总之,LMWH的血浆脂解作用明显弱于肝素。肝素与LPL之间的复合物结合取决于肝素的硫酸化程度或离子强度。然而,在从组织制剂中释放LPL时,肝素的分子大小具有更重要的意义。无论两种肝素制剂的血浆脂解活性程度如何,脂肪氧化率均不受影响。考虑到高血浆FFA水平的毒性作用,具有较弱脂解潜力的LMWH作为抗凝剂似乎比肝素更可取。